vimarsana.com

Latest Breaking News On - Professor zeng xiaofeng - Page 1 : vimarsana.com

RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren s Syndrome

/PRNewswire/ RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced significant.

United statesZhang hongJianmin fangZeng xiaofengRemegen co ltdUnion medical college hospitalNational medical products administrationPrnewswire remegen coRemegen coUniversity first hospitalProfessor zhang hongPeking university firstProfessor zeng xiaofengPeking union medical collegeMultidimensional fatigue inventory

RemeGen s Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren s Syndrome: Findings Published in Prestigious Rheumatology Journal

/PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, has.

United kingdomUnited statesZeng xiaofengJianmin fangUnion medical college hospitalDepartment of rheumatologyOxford universityRemegen coBritish society for rheumatologyOxford university pressPrnewswire remegen co ltdBritish societyProfessor zeng xiaofengPeking union medical college hospitalChief scientific officerRemegen co

vimarsana © 2020. All Rights Reserved.